Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.

MLA

Freedman, Orit, et al. “Predicting Benefit from Fulvestrant in Pretreated Metastatic Breast Cancer Patients.” Breast Cancer Research & Treatment, vol. 118, no. 2, Jan. 2010, pp. 377–83. EBSCOhost, https://doi.org/10.1007/s10549-009-0452-8.

APA

Freedman, O., Amir, E., Dranitsaris, G., Napolskikh, J., Kumar, R., Fralick, M., Chia, S., Petrella, T., Dent, S., Tonkin, K., Ahmad, I., Rayson, D., & Clemons, M. (2010). Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Research & Treatment, 118(2), 377–383. https://doi.org/10.1007/s10549-009-0452-8

Chicago

Freedman, Orit, Eitan Amir, George Dranitsaris, Julie Napolskikh, Ritu Kumar, Michael Fralick, Stephen Chia, et al. 2010. “Predicting Benefit from Fulvestrant in Pretreated Metastatic Breast Cancer Patients.” Breast Cancer Research & Treatment 118 (2): 377–83. doi:10.1007/s10549-009-0452-8.